Below are several PD-related medical marijuana studies that have been conducted to evaluate the use of cannabinoids in Parkinson’s:
- The Therapeutic Potential of Cannabinoids for Movement Disorders: clinical observations and trials of cannabinoid-based therapies suggest a possible benefit to tics and probably no benefit for tremor in dyskinesias or PD motor symptoms. Further preclinical and clinical research is needed to better characterize the pharmacological, physiological and therapeutic effects of this class of drugs in movement disorders.
- Cannabinoids Reduce Levodopa-induced Dyskinesia in Parkinson’s Disease: A Pilot Study: the authors demonstrate that nabilone, the cannabinoid receptor agonist, significantly reduces levodopa-induced dyskinesia in PD.
- Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease: evaluation of the effects of three antagonists on the NK3, neurotensin and cannabinoid receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson’s. The study concluded that the drugs tested were safe, but did not improve parkinsonian motor disability.
- The Endocannabinoid System as an Emerging Target of Pharmacotherapy: reviews the endocannabinoid system and its regulatory functions in health and disease.
Read More : http://www.parkinson.org/understanding-parkinsons/treatment/complementary-treatment/medical-marijuana-and-parkinsons-disease